

MATERIAL CHANGE REPORT UNDER SECTION 85(1) OF THE ACT

Item 1. Reporting Issuer

Frequency Exchange Corp. (the “**Company**”)
1498 West 5th Avenue
Vancouver, BC V6H 4G3

Item 2. Date of Material Change

February 4, 2026

Item 3. News Release

News release dated February 4, 2026 was disseminated and subsequently filed on SEDAR+ and through the facilities of Stockwatch.

Item 4. Summary of Material Change

Frequency Exchange Corp. issues the news release to amend its news release dated February 3, 2026 to correct the option exercise price from \$0.25 to \$0.33.

Item 5. Full Description of Material Change

See attached press release.

Item 6. Reliance on Section 85(2) of the Act

N/A

Item 7. Omitted Information

None

Item 8. Senior Officers

The following senior officers of the Issuer are knowledgeable about the material change and may be contacted by the Commission at the address and telephone number:

Stephen Davis
President & CEO
(250) 732-7170

Hari Varshney
Director
(604) 684-2181

The foregoing accurately discloses the material change referred to herein.

Dated this 4th Day of February, 2026

"Hari Varshney"

Hari Varshney

Name

Director

Position / Title

Vancouver, B.C.

Place of Declaration

FOR IMMEDIATE RELEASE

FREQUENCY EXCHANGE ANNOUNCES CORRECTION TO PRESS RELEASE ANNOUNCING STOCK OPTION GRANT

Vancouver, British Columbia, Canada – February 4, 2026 – Frequency Exchange Corp. (“Frequency Exchange” or the “Company”) (TSXV: **FREQ**) issues the following news release to amend its news release dated February 3, 2026 to correct the option exercise price from \$0.25 to \$0.33.

The complete corrected news release is below:

Frequency Exchange Corp. (“Frequency Exchange” or the “Company”) (TSXV: **FREQ**) announces that the Company has granted 120,000 stock options to an officer of the Company, exercisable for a period of 3 years, at a price of \$0.33 per share. The grant of the Options is subject to regulatory approval.

About the Company

Based in British Columbia, Canada, FREmedica is focused on the development and global commercialization of a wearable Frequency Delivery System providing specialized programs designed for health and wellness as well as performance enhancement. NIKKI is the fifth-generation Frequency Delivery System released by the Company, initially to help clients with chronic Lyme disease. This wearable frequency technology is the product of years of research and development applying the latest in bioenergetic science.

www.WeAreNikki.com

www.Fremedica.com

www.FrequencyExchangeCorp.com

For more information, please contact:

Frequency Exchange Corp.
Stephen Davis
CEO & Director
250-732-7170

FREmedica Technologies Inc.
Nicole Sullivan
President
nicole@fremedica.com

Disclaimer for Forward-Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation including the proposed Private Placement and use of proceeds. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Forward-looking information in this news release includes statements concerning the Company's general business plans. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Final Prospectus, and the schedules attached thereto, that are available on the Company's profile on SEDAR+ at www.sedarplus.ca.

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.